SCHEMBL22843532

SCHEMBL22843532

O=c1c2ncn([C@@H]3O[C@H](COP(=O)(O)CP(=O)(O)O)C(O)(O)[C@H]3O)c2ncn1Cc1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
NT5E P21589 18/20 0.57
TYMP P19971 1/20 0.52
PLCG1 P19174 1/20 0.44
ENPP1 P22413 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21349010 0.85 TYMP (0.69) NT5ETYMPPLCG1ENPP1
SCHEMBL22843547 0.81 NT5E (0.75) NT5E
SCHEMBL22843641 0.79 NT5E (0.86) NT5E
SCHEMBL22843631 0.77 NT5E (0.76) NT5E
SCHEMBL22843492 0.77 NT5E (0.68) NT5E
SCHEMBL22843637 0.76 NT5E (0.76) NT5E
SCHEMBL22843543 0.76 NT5E (0.76) NT5E
SCHEMBL22843692 0.76 NT5E (0.76) NT5E
SCHEMBL22843700 0.76 NT5E (0.71) NT5E
SCHEMBL23914896 0.75 TYMP (0.71) NT5ETYMP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200405629-A1 PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS ARCUS BIOSCIENCES, INC. 2020-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200405629-A1 PARENTERALLY ADMINISTERED IMMUNE ENHANCING DRUGS NT5C2, ADA, ENTPD1 NT5E 10/4885TYMP 38/4885PLCG1 523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.